Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.
about
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cellsTargeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
P2860
Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.
@ast
Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.
@en
type
label
Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.
@ast
Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.
@en
prefLabel
Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.
@ast
Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.
@en
P2860
P356
P1433
P1476
Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro
@en
P2093
Herbert Chen
Yash Somnay
P2860
P304
P356
10.1159/000341810
P577
2012-09-04T00:00:00Z